AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Other Events
Item 8.01 Other Events.

On March22, 2018, Akebia Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley& Co. LLC, as underwriter (the “Underwriter”), related to a public offering (the “Offering”) of 8,500,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”), at a price to the public of $10.50 per share, to an automatically effective shelf registration statement (File No.333-223585) and a related prospectus supplement. In addition, the Company granted the Underwriter an option to purchase, at the public offering price less any underwriting discounts and commissions, an additional 1,275,000 shares of Common Stock, exercisable for 30 days from the date of the prospectus supplement. Subject to customary closing conditions, the Offering is expected to close on March27, 2018.

The above description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated herein by reference.

An opinion dated March 26, 2018 regarding the legality of the issuance and sale of the Shares in the Offering, including the additional shares the underwriters have the option to purchase to the Underwriting Agreement, is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Item 8.01 Financial Statements and Exhibits.

2

Akebia Therapeutics, Inc. Exhibit
EX-1.1 2 d361054dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version 8,…
To view the full exhibit click here

About AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.